Cationic nanoparticle complexes encapsulating paclitaxel and the Bcl-2 gene have been shown to inhibit drug-resistant liver cancer cells by disrupting P-glycoprotein (P-gp) drug efflux and activating apoptotic pathways [257]. This evidence concerns the gene BCL2 and liver cancer.